

National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No.2) 2019

I, Hope Peisley, make the following Determination.

Dated 5 November 2019

Ms Hope Peisley

Acting Assistant Secretary
Office of Health Protection
Chief Medical Officer Group
Department of Health

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No.1) 2

1 Name

 This instrument is the *National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No.2) 2019.*

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | On the day after this instrument is registered. |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 9B(2) and 9B(5) of the *National Health Act 1953.*

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No.1)

1 After Subsection 7(8A)

Insert:

(8B) For items 207F of Schedule 1, a designated vaccine mentioned in this

 item may be provided to:

 (a) a person who is at least 65 years; or

 (b) an Aboriginal or Torres Strait Islander person who is at least 6 months; or

(c) a child who is at least 6 months old but less than 5 years old;

(d) a person who is at least 6 months who:

(i) has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or

(ii) has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or

(iii) has another chronic illness requiring regular medical follow‑up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug‑induced immune impairment); or

(iv) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or

(v) has impaired immunity, including HIV infection; or

(vi) is less than 11 years and is receiving long term aspirin therapy; or

(e) a woman who is pregnant.

2 Part 2 of Schedule 1 (table item 202A, column headed “Vaccine and the circumstances in which vaccine may be provided”, subparagraph (iii) under subheading “Circumstances”)

Omit “2019”, substitute “2020”.

3 Part 2 of Schedule 1 (after table item 207E)

Insert:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 207F | **Vaccine**Influenza**Circumstances**Vaccine may be provided in the circumstances set out in subsection 7(8B) | VaxiGrip Tetra | Injection (0.5mL) |  | For children older than 6 months but less than 9 years, 2 doses at least 1month apart for the first vaccination and 1 dose per calendar year after that. For persons 9 years and above, 1 dose per calendar year. |